Leif Thuesen mainly investigates Surgery, Internal medicine, Myocardial infarction, Cardiology and Angioplasty. The Surgery study combines topics in areas such as Coronary artery disease and Percutaneous coronary intervention. His Internal medicine research is multidisciplinary, incorporating perspectives in Placebo and Endocrinology.
In general Myocardial infarction study, his work on Conventional PCI and Target lesion often relates to the realm of In patient, thereby connecting several areas of interest. His research integrates issues of Stroke and Clinical trial in his study of Cardiology. His study looks at the intersection of Angioplasty and topics like Revascularization with Paclitaxel, Major complication, Patient age, Percutaneous and Long term outcomes.
His primary areas of investigation include Internal medicine, Cardiology, Surgery, Myocardial infarction and Percutaneous coronary intervention. His work in the fields of Conventional PCI, Hazard ratio and Sirolimus overlaps with other areas such as In patient. His work carried out in the field of Cardiology brings together such families of science as Stroke and Coronary stent.
His biological study spans a wide range of topics, including Nuclear medicine and Cohort. His studies deal with areas such as Thrombosis and Randomized controlled trial as well as Myocardial infarction. His Stent study combines topics from a wide range of disciplines, such as Coronary artery disease and Mace.
His scientific interests lie mostly in Internal medicine, Cardiology, Surgery, Myocardial infarction and Percutaneous coronary intervention. His work on Hazard ratio, Sirolimus and Stroke is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science. His Cardiology research is multidisciplinary, incorporating elements of Restenosis and Coronary stent.
His research investigates the connection between Surgery and topics such as Clopidogrel that intersect with problems in Discontinuation. The various areas that Leif Thuesen examines in his Myocardial infarction study include Thrombosis and Proportional hazards model. His Percutaneous coronary intervention study also includes
His main research concerns Myocardial infarction, Surgery, Internal medicine, Cardiology and Percutaneous coronary intervention. He combines subjects such as Restenosis and Hazard ratio with his study of Myocardial infarction. The study incorporates disciplines such as Coronary artery disease, Stent thrombosis and Nuclear medicine in addition to Surgery.
Leif Thuesen works mostly in the field of Cardiology, limiting it down to topics relating to Stroke and, in certain cases, Relative risk. The concepts of his Percutaneous coronary intervention study are interwoven with issues in ST segment, Angioplasty, Coronary occlusion and Intention-to-treat analysis. His Angioplasty research is multidisciplinary, relying on both Framingham Risk Score and Balloon.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Comparison of Coronary Angioplasty with Fibrinolytic Therapy in Acute Myocardial Infarction
Henning R. Andersen;Torsten T. Nielsen;Klaus Rasmussen;Leif Thuesen.
The New England Journal of Medicine (2003)
Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome
Henning Rud Andersen;Jens Cosedis Nielsen;Poul Erik Bloch Thomsen;Leif Thuesen.
The Lancet (1997)
BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
J O Jørgensen;S A Pedersen;L Thuesen;J Jørgensen.
The Lancet (1989)
Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study
Terje K. Steigen;Michael Maeng;Rune Wiseth;Andrejs Erglis.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
Patrick W Serruys;John A Ormiston;Yoshinobu Onuma;Evelyn Regar.
The Lancet (2009)
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
John A Ormiston;Patrick W Serruys;Evelyn Regar;Dariusz Dudek.
The Lancet (2008)
Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial
Hans Erik Bøtker;Rajesh Kharbanda;Michael R Schmidt;Morten Bøttcher.
The Lancet (2010)
Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes
Patrick W. Serruys;Yoshinobu Onuma;Dariusz Dudek;Pieter C. Smits.
Journal of the American College of Cardiology (2010)
System Delay and Mortality Among Patients With STEMI Treated With Primary Percutaneous Coronary Intervention
Christian Juhl Terkelsen;Jacob Thorsted Sørensen;Michael Maeng;Lisette Okkels Jensen.
Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome
H.R Andersen;L Thuesen;J.P Bagger;T Vesterlund.
The Lancet (1994)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: